After 15 years of success - Perspectives of erythropoietin therapy

Nephrology Dialysis Transplantation

Volumn 16, Issue 9, 2001, Pages 1745-1749

  Eckardt, Kai Uwe ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Erythropoietin therapy

Indexed keywords

COMPLEMENTARY DNA; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; BRAIN INJURY; CONTROLLED STUDY; CRITICAL ILLNESS; DIALYSIS; DRUG HALF LIFE; DRUG INDICATION; DRUG TARGETING; GENE ACTIVATION; GENE THERAPY; GENE TRANSFER; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; INTENSIVE CARE; MOLECULAR MIMICRY; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0034852368     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.9.1745     Document Type: Article

References (34)

1. Hematocrit level and associated mortality in hemodialysis patients
2. Cardiovascular consequences of renal anaemia and erythropoietin therapy
3. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease
4. Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin
5. European survey of anaemia management: Evaluating anaemia and initiating treatment
6. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class and hospitalizations
7. Aggressive therapy of congestive heart failure and associated chronic renal failure with medications and correction of anemia slows or stops the progression of both diseases
8. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
9. Important role of non-diagnostic blood loss and diminished erythropoietic response in the anemia of medical intensive care patients
10. Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized double blind placebo controlled trial
11. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care
12. Organ distribution of erythropoietin messenger RNA in normal and uremic rats
13. Erythropoietin gene expression in human, monkey and murine brain
14. Erythropoietin is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death
15. In vivo evidence that erythropoietin protects neurons from ischemic damage
16. A potential role for erythropoietin in focal permanent cerebral ischemia in mice
17. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury
18. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients
19. Novel erythropoiesis stimulating protein (NESP) maintains hemoglobin (Hb) in ESRD patients when administered once weekly or once every other week
20. Novel erythropoiesis stimulating protein (NESP) effectively maintains hemoglobin (Hb) when administered at a reduced dose frequency compared with recombinant human erythropoietin (rHuEpo) in ESRD patients
21. The efficacy of once weekly compared with two or three times weekly subcutaneous Epoetin beta: Results from a randomized controlled multicentre trial
22. The structure, organization, activation and plasticity of the erythropoietin receptor
23. Functional mimicry of a protein hormone by a peptide agonist: The Epo receptor complex at 2.8 Å
24. Mimicry of erythropoietin by a nonpeptide molecule
25. Erythropoietin mimetic peptides and the future
26. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals
27. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis
28. Myoblast transfer of human erythropoietin gene in a mouse model of renal failure
29. Long-term erythropoietin expression in rodents and non-human primates following intramuscular injection of a replication-defective adenoviral vector
30. A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension
31. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer
32. Ligand-dependent regulation of vascular endothelial growth factor and erythropoietin expression by a plasmid-based autoinducible GeneSwitch system
33. Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector
34. European best practice guidelines for the management of anaemia in patients with chronic renal failure